dc.contributor.author | Yazihan, Nuray | |
dc.contributor.author | Aras, YAVUZ | |
dc.contributor.author | Bilir, Ayhan | |
dc.contributor.author | Aktas, Esin | |
dc.contributor.author | Erguven, Mine | |
dc.date.accessioned | 2021-03-05T15:37:02Z | |
dc.date.available | 2021-03-05T15:37:02Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Aras Y., Erguven M., Aktas E., Yazihan N., Bilir A., "Antagonist activity of the antipsychotic drug lithium chloride and the antileukemic drug imatinib mesylate during glioblastoma treatment in vitro", NEUROLOGICAL RESEARCH, cilt.38, ss.766-774, 2016 | |
dc.identifier.issn | 0161-6412 | |
dc.identifier.other | av_bca8eca8-5722-49c5-9077-432cc0e0bead | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/125394 | |
dc.identifier.uri | https://doi.org/10.1080/01616412.2016.1203096 | |
dc.description.abstract | Objectives: Glioblastoma (GBM), the most common primary tumour of the central nervous system, is characterised by a high malignancy and poor prognosis. The aims of this study were to investigate whether the combination of imatinib mesylate (IM) and lithium chloride (LiCl) exhibited a synergistic effect in treatment and to determine whether midkine (MK) affected the fate of this treatment in vitro. | |
dc.language.iso | eng | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Nöroloji | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Temel Bilimler | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | Sinirbilim ve Davranış | |
dc.subject | NEUROSCIENCES | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | KLİNİK NEUROLOJİ | |
dc.title | Antagonist activity of the antipsychotic drug lithium chloride and the antileukemic drug imatinib mesylate during glioblastoma treatment in vitro | |
dc.type | Makale | |
dc.relation.journal | NEUROLOGICAL RESEARCH | |
dc.contributor.department | İstanbul Aydın Üniversitesi , , | |
dc.identifier.volume | 38 | |
dc.identifier.issue | 9 | |
dc.identifier.startpage | 766 | |
dc.identifier.endpage | 774 | |
dc.contributor.firstauthorID | 71478 | |